MetLife (MET) has experienced significant activity within various investment organizations. Wellington Management Group LLP, Raymond James Financial Inc, and Candriam S.C.A are a few of the bodies with notable stakes in MetLife. Moreover, major purchases of shares have been made by Edgar Lomax Co VA, Price T Rowe Associates Inc, and HighTower Advisors LLC, among others.
While MetLife witnessed five days of gains resulting in a 5.4% return, the stock outlook is viewed as bearishly technical despite mixed analyst and fundamentals. Strategic shifting and digital partnerships have driven a minor rally. However, reports suggest that MetLife missed Q2 revenue estimates, causing a decline in its stocks.
Post Q1 earnings, the stock's price target was lowered to $94 from $98 at Morgan Stanley. Notwithstanding, the company managed to declare dividends for both Preferred and Common Stock in Q3 2025. Amid disappointing Q2 earnings attributed to less favorable underwriting and lower investment margins, price targets have been adjusted by different analysts, including a decrease to $92 by Keefe, Bruyette & Woods and an increase to $103 by Jefferies Financial Group.
Metlife MET News Analytics from Wed, 11 Dec 2024 08:00:00 GMT to Sat, 23 Aug 2025 13:03:36 GMT - Rating 0 - Innovation -5 - Information 7 - Rumor -1
